Pamela D H Kowalczyk, MD | |
114 Woodland Street, Department Of Pathology, Hartford, CT 06105 | |
(860) 714-4280 | |
(860) 714-8021 |
Full Name | Pamela D H Kowalczyk |
---|---|
Gender | Female |
Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
Location | 114 Woodland Street, Hartford, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114986171 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 026168 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Pamela D H Kowalczyk, MD 15 Mals Way, Unionville, CT 06085 Ph: (860) 675-1318 | Pamela D H Kowalczyk, MD 114 Woodland Street, Department Of Pathology, Hartford, CT 06105 Ph: (860) 714-4280 |
News Archive
The three judges ruled that the measles-mumps-rubella vaccine (MMR), given in combination with thimerosal-containing vaccines, does not cause autism.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced data from a Phase 2 clinical trial that demonstrated Positron Emission Tomography myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography myocardial perfusion imaging, the current standard for the non-invasive detection of CAD.
The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Scientists at the University of Toronto are taking regenerative medicine to a new dimension with a process for guiding nerve cells that could someday help reconnect severed nerve endings.
› Verified 6 days ago
Nalini Y Masih, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: Disability Determination Services, 309 Wawarme Ave, Hartford, CT 06114 Phone: 860-466-6226 | |
Dr. Andrew Ricci Jr Jr., MD Pathology Medicare: Medicare Enrolled Practice Location: 80 Seymour Street, Hartford, CT 06102 Phone: 860-545-2249 Fax: 860-545-2249 | |
Gualberto Ruano, MD, PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 67 Jefferson St, Hartford, CT 06106 Phone: 860-545-4574 | |
Lisa Barnett, Pathology Medicare: Not Enrolled in Medicare Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-4292 | |
Dr. I-sanna R. Gibbons-fideler, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-2249 Fax: 860-282-0170 | |
Muhammad S Qazi, M.D Pathology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour Street, Hartford, CT 06102 Phone: 860-972-2249 Fax: 860-282-0170 |